<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00454714</url>
  </required_header>
  <id_info>
    <org_study_id>RBK091</org_study_id>
    <nct_id>NCT00454714</nct_id>
  </id_info>
  <brief_title>Therapeutic Effect of Sildenafil in Patients With Coronary Vasospasm</brief_title>
  <official_title>Application of Sildenafil in Patients With Documented Coronary Vasospasm to Explore the Pathophysiology of Coronary Vasospasm and the Therapeutic Effect of Sildenafil in Patients Suffering From Coronary Vasospasm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Udo Sechtem</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Robert Bosch Gesellschaft für Medizinische Forschung mbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a prospective, phase IIIb, double-blind and randomized trial testing the effect&#xD;
      of single dose sildenafil application in patients with coronary vasospasm compared to placebo&#xD;
      application.&#xD;
&#xD;
      The target variable to be tested is the degree of coronary vasoconstriction in response to&#xD;
      intracoronary ACh application (in addition to clinical chest pain) which will be imaged by&#xD;
      coronary angiography and measured using quantitative coronary angiography software.&#xD;
&#xD;
      Main objective: Has sildenafil the potency to inhibit the induction of coronary vasospasm by&#xD;
      intracoronary ACh-application in patients with proven coronary artery spasm?&#xD;
&#xD;
      Secondary objective: Which degree of coronary vasospasm inhibition can be achieved with&#xD;
      sildenafil?&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronary artery spasm is an abrupt severe vasoconstrictor response which may occur&#xD;
      spontaneously in normal and diseased coronary arteries. It may result in myocardial ischemia&#xD;
      and may be provoked by various stimuli such as acetylcholine (ACh). Coronary vasospasm is&#xD;
      involved in the pathogenesis of Prinzmetal's angina, acute myocardial infarction or sudden&#xD;
      cardiac death due to ventricular arrythmias and chest pain symptoms associated with viral&#xD;
      myocarditis.&#xD;
&#xD;
      The precise cellular and molecular mechanisms of coronary vasospasm have not yet been&#xD;
      elucidated. The most often suggested but competing explanations for this disease are coronary&#xD;
      endothelial dysfunction secondary to impaired nitric oxide production versus coronary smooth&#xD;
      muscle cell hyperreactivity with or without additional endothelial dysfunction. As the&#xD;
      precise cellular mechanism is currently unknown a large group of people can currently not be&#xD;
      treated appropriately despite the use of nitrates and calcium antagonists.&#xD;
&#xD;
      Sildenafil is a phosphodiesterase(PDE)-5 inhibitor approved for the treatment of both&#xD;
      erectile dysfunction and pulmonary hypertension. PDE-5 has been shown to be also present and&#xD;
      play an important vasomotor role in the coronary vessel wall. Application of the inhibitor&#xD;
      sildenafil has been shown to increase the resting coronary artery diameter. Furthermore,&#xD;
      atherosclerotic coronary artery segments which vasoconstrict following intracoronary&#xD;
      ACh-application vasodilate following the application of sildenafil when ACh-testing is&#xD;
      repeated. Other studies are also suggesting an improved endothelial function after sildenafil&#xD;
      application for both the coronary and the peripheral vasculature.&#xD;
&#xD;
      Taken together, sildenafil is expected to have a positive effect on coronary vasomotility.&#xD;
      Whether sildenafil can totally prevent the occurrence of coronary vasospasm or at least&#xD;
      decrease the severity of vasospasm has not been studied so far. Thus, the aim of this study&#xD;
      is to analyse the possible anti-spastic effects of sildenafil in patients suffering from&#xD;
      coronary vasospasm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study not started&#xD;
  </why_stopped>
  <start_date>March 1, 2007</start_date>
  <completion_date type="Actual">December 31, 2009</completion_date>
  <primary_completion_date type="Actual">December 31, 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of coronary vasospasm in spite of medical treatment</measure>
    <time_frame>After inclusion of last patient</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Coronary Vasospasm</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sildenafil arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>single dose Sildenafil</intervention_name>
    <description>Application of a single dose Sildenafil</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Single dose placebo</intervention_name>
    <description>Application of a single dose placebo</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age ≥ 50y&#xD;
&#xD;
          -  Framingham risk score &lt; 10%&#xD;
&#xD;
          -  no contraindication to sildenafil application&#xD;
&#xD;
          -  clinical history of atypical angina pectoris&#xD;
&#xD;
          -  exclusion of significant coronary artery disease (stenosis ≥ 50%) by coronary&#xD;
             angiography&#xD;
&#xD;
          -  documented coronary spasm by ACh-testing in at least one coronary artery segment&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  existing contraindication to sildenafil application&#xD;
&#xD;
          -  significant coronary artery disease (≥ 50%)&#xD;
&#xD;
          -  valvular, inflammatory, dilative or other cardiomyopathies&#xD;
&#xD;
          -  congestive heart failure (left ventricular ejection fraction &lt; 60%) of any reason&#xD;
&#xD;
          -  need for therapeutic treatment with nitrates or intake of any nitrates in the last 24h&#xD;
             before coronary angiography&#xD;
&#xD;
          -  participation in another clinical trial at the moment or in the last 30 days&#xD;
&#xD;
          -  hypotonic blood pressure (&lt;90/50mmHg)&#xD;
&#xD;
          -  hepatic insufficiency (&gt; Child-Pugh-classification A)&#xD;
&#xD;
          -  renal insufficiency with a GFR &lt; 60ml/min- pregnancy or lactation&#xD;
&#xD;
          -  not able to consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Udo Sechtem, MD</last_name>
    <role>Study Director</role>
    <affiliation>Robert Bosch-Krankenhaus Stuttgart</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>March 29, 2007</study_first_submitted>
  <study_first_submitted_qc>March 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2007</study_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Robert Bosch Gesellschaft für Medizinische Forschung mbH</investigator_affiliation>
    <investigator_full_name>Udo Sechtem</investigator_full_name>
    <investigator_title>Prof. Udo Sechtem</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Vasospasm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

